Novo Nordisk Raises 2026 Outlook as Wegovy Pill Sales Reach DKK 5.394B
Photo: TokenPost
Novo Nordisk raised its 2026 outlook for sales and operating profit after its Wegovy pill generated DKK 5.394 billion in third-quarter sales across four markets, including the United States. The company now expects adjusted sales and adjusted operating profit to each range from a 2% decline to 2% growth this year at constant exchange rates. Its previous outlook allowed declines of up to 6% or flat results for both measures. The improved outlook reflects higher expectations for GLP-1 product sales. The pill was available in the United States, the United Arab Emirates, the United Kingdom and Germany by quarter-end.
Source: TokenPost
